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Use of CCR5 antagonists requires previous viral tropism determination. The available
methods have high cost, are time-consuming, or require highly trained personnel, and
sophisticated equipment. We  compared a ﬂow cytometry-based tropism assay with
geno2pheno method to determine HIV-1 tropism in AIDS patients, in Bahia, Brazil. We  tested
peripheral blood mononuclear cells of 102 AIDS patients under antiretroviral therapy by
using a cytometry-based tropism assay and geno2pheno assay. Cellular membrane recep-
tors  were identiﬁed by using CXCR4, CCR5 and CD4 monoclonal antibodies, while detection
of  cytoplasmic mRNAs for gag and pol HIV regions was achieved by using a labeled probe.
Genotypic identiﬁcation of X4 and R5 tropic viruses was attempted by geno2pheno algo-
rithm. There was a high degree of concordance between cytometry-based tropism assay and
geno2pheno algorithm in determination of HIV-1 tropism. Cytometry-based tropism assay
demonstrated higher sensitivity and speciﬁcity in comparison to geno2pheno, which was
used  as a gold-standard. One sample could not be ampliﬁed by geno2pheno method, but was
classiﬁed as duotropic by cytometry-based tropism assay. We  did not ﬁnd any association
between CD4+ count or plasma HIV-1 RNA viral load and tropism results. The overall per-formances of cytometry-based tropism assay and geno2pheno assay were almost identical
in  determination of HIV-1 tropism.
© 2015 Elsevier Editora Ltda. All rights reserved.∗ Corresponding author.
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Introduction
To enter the host cells, HIV-1 requires an initial attachment
to cells membrane’s CD4 receptor, which leads to an inter-
action between the viral envelope (gp120) and one of the
cellular coreceptors: CCR5 or CXCR4.1,2 This step is essen-
tial to enable the fusion of viral envelope and host cell
membrane, and to allow the introduction of viral genome
into cell cytoplasm.3 It was demonstrated that CCR5-tropic
viruses predominate during the initial phases of infection,
whereas CXCR4-binding viruses usually emerge in a later
phase, and are associated with a faster CD4+ T-cell decline
and progression to AIDS.4 Most HIV variants isolated from
drug-naive, chronically infected individuals, use CCR5 along
with CD4 to enter T cells (R5 tropic viruses). On the other
hand, viruses able to use CXCR4 coreceptors (X4-tropic)
tend to emerge later in the course of HIV infection, in
comparison with R5 strains, and are recognized in nearly
half of patients with advanced disease stages. Coreceptor
switch may occur overtime in patients under antiretroviral
therapy.5
CCR5 antagonists are a relatively new class of drugs that
block HIV entry into target cells. These drugs bind to a
hydrophobic pocket formed by the transmembrane helices
of CCR5, and induce conformational changes in the extra-
cellular loops (ECLs) of the receptor. Since they are active
only against R5 viruses, it is necessary to determine the viral
tropism previously to the use of CCR5 antagonists in HIV
treatment.6–12
Different genotypic and phenotypic tools have been used
to deﬁne HIV tropism.13,14 The viral tropism has been deter-
mined by using phenotypic methods (like Monogram’s Troﬁle),
by sequencing the V3 loop of HIV envelope, and by ﬂow
cytometry-based assays.15–17 Despite some recent improve-
ments, genotypic algorithms are still restricted to referral
laboratories, and their predictive values have limitations.18–20
Recently, a new algorithm (geno2pheno) showed a good
correlation with phenotypic methods.21 Another genotypic
approach is ultra-deep sequencing, but it is expensive,
requires sophisticated equipment, and is not applicable to
daily clinical practice.22
Currently, the most used tropism assays are phenotypic-
(“Troﬁle”) or genotyping-based tests (geno2pheno). Both tests
share some practical limitations, such as high cost, prolonged
time to obtain a conﬁrmed result, availability, considerable
proportion of “nonreportable” results, the requirement of
samples with a detectable level of HIV RNA copies/ml, and
limited access in developing countries.23 Flow cytometry
tropism assay (FCTA) was initially developed as a commer-
cially available method (ViroTect Tropism Assay, Invirion
Diagnostics, USA), based on ﬂuorescence-activated cell sor-
ting, with a turnaround time of 3 h (Invirion Diagnostics, 2007),
and a signiﬁcantly lower cost, in comparison with the above
described methods.
In the present study, we  compared the performance of an
in-house ﬂow cytometry-based assay, with geno2pheno
assay for determination of viral tropism in periph-
eral blood mononuclear cells (PBMC) of HIV-infected
patients. 1 5;1  9(2):163–169
Material  and  methods
We evaluated viral tropism of HIV strains in PBMC of 102
consecutive HIV-1-infected patients, who attended the AIDS
outpatient clinic of Hospital Universitário Professor Edgard
Santos, Federal University of Bahia, Brazil. Patients assigned to
routine evaluation of HIV viral load, and CD4/CD8+ cell count
were invited to enter the study. The institutional ethics review
committee approved the study, and patients were recruited
after signing a written informed consent.
Flow  cytometry  tropism  assay  procedure
Determination of HIV-1 tropism by FCTA was performed by
mRNA  in situ hybridization (FISH), combined with T cell
immunophenotyping to deﬁne expression of CCR5 and/or
CXCR4 coreceptors. A labeled probe detected epitopes of Gag
and pol HIV-1 regions.15
Brieﬂy, we ﬁxed and permeabilized PBMC with speciﬁc
buffers. After washing with PBS, a mRNA  probe labeled with
6-FAM ﬂuorophore and an integration buffer were added to
cell suspension, and incubated for 2 h in warm bath in the
dark. The samples were submitted to a new washing step, and
monoclonal antibodies to CD4 (labeled with APC), to CXCR4
(PE), and to CCR5 (PerCP) were added, before acquisition and
analysis by BD CellQuest software from FACSCalibur, with four
ﬂuorimetric parameters.
HIV-1  env  genetic  sequencing
PBMC DNA was extracted by QIAGEN protocol. Ampliﬁcation
of partial HIV envelope (env) gene by nested PCR was performed
with 2.5 L of DNA input. Reaction mixture included 10 M of
each primer ED5, forward position ATG GGA TCA AAG CCT
AAA GCC ATG TG (6557 → 6582) and ED12, reverse position
AGT GCT TCC TGC TGC TCC CAA GAA CCC AAG (7811 ← 7782)
with Taq Platinum High Fidelity (Invitrogen) in a ﬁnal volume
reaction of 25 L. Positive and negative controls were included
in each run. PCR conditions consisted of 10 cycles 94 ◦C 2 min,
94 ◦C 15 s, 55 ◦C 30 s, 68 ◦C 1 min, 25 cycles 94 ◦C 15 s, 55 ◦C 30 s,
68 ◦C 1 min  add 5 s/cycle, and 68 ◦C 7 min; 2.5 Ul of PCR prod-
ucts were used in a second PCR (nested) with primers ED31,
forward position CCT CAG CCA TTA CAC AGG CCT GTC CAA AG
(6817 → 6845) and ES8, reverse position CAC TTC TCC AAT TGT
CCC TCA (7668 ← 7648) with Taq DNA Polymerase (Invitrogen)
in a ﬁnal volume reaction of 25 L.
PCR conditions consisted of 10 cycles 94 ◦C 2 min, 94 ◦C
15 s, 55 ◦C 30 s, 72 ◦C 1 min, 25 cycles 94 ◦C 15 s, 55 ◦C 30 s,
72 ◦C 1 min  (increasing by 5 s in each sequential elongation),
with a ﬁnal elongation period at 72 ◦C 1 min, add 5 s/cycle.
PCR reaction was considered valid when the PCR products
and positive control bands were visualized around 700 bp at
1.3% agarose gel with SYBR Safe DNA gel staining (Invitro-
gen, USA) along with controls. Nested PCR products were
quantiﬁed using low mass ladder (Invitrogen, USA), diluted
accordingly (1:10) in water to allow an input of 5–10 nanograms
of DNA for rodamine incorporation. Big Dye Kit (Ready Reac-
tion Mix, Applied Biosystems, Foster City, CA) was used with
the primers V3O2, forward position 5′ AAT GTC AGY ACA GTA
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AA TGT ACA C 3′ (6948 → 6969), ES7, forward position 5′ CTG
TA AAT GGC AGT CTA GC 3′ (7005 → 7021), ED33 reverse posi-
ion 5′ TTA CAG TAG AAA AAT TCC CCT C 3′ (7360 ← 7378) and
QV3, reverse position 5′ GAA AAA TTC CCT TCC ACA ATT AAA
′ (7350 ← 7370). Cycle sequencing conditions consisted of 25
ycles 96 ◦C 10 s, 50 ◦C 5 s, 60 ◦C 4 min, 8 ◦C inﬁnity. After cycle
equencing, DNA precipitation (using a solution of sodium
cetate and ethanol) was followed by denaturation using Hi-
i Formamide at 94 ◦C 4 min  and resolved at an automated
equencer Genetic Analyzer 3130 XL (Applied Biosystems).
equences were edited using Sequencer (Biocodes, USA) and
ubmitted to geno2pheno evaluation (Max Planck Institute,
ermany) using clonal option.
Statistical parameters were analyzed by SPSS v.17 software.
CTA and geno2pheno results were compared and evaluated
y Pearson Chi-square test. Sensitivity, speciﬁcity and positive
PPV) and negative (NPV) predictive values were also calcu-
ated between the two assays.
esults
 total of 102 PBMC samples from HIV infected patients were
valuated. Median age was 42 years. The median CD4+ lym-
hocyte count was 489 cells/mm3 (IQR: 305–675), CD8+ was
86 cells/mm3 (IQR: 716–1229), and CD3+ was 1529 cells/mm3
IQR: 1187–1946). The mean elapsed time since HIV diagnosis
as  six years (range 2–6 years). Sixty-six patients presented
ith undetectable HIV viral load, while 28 had a viral load
igher than 1500 copies/ml. Eight patients did not have an
vailable viral load measurement in the past 12 months.
Initially, we  used gate strategy Side Scatter versus CD4+
n dot plot FCTA analysis for selection of monocytes and
ymphocytes. In the sequence, CD4+CCR5+ and CD4+CXCR4+
ositive events were isolated in two different gates. In each
ate CCR5+ was plotted versus CXCR4+. A gate was selected for
CR5+CXCR4− cells, and analyzed to detect HIV-1 probe versus
D4+ cells in other plot. The same procedure was performed
o identify CCR5−CXCR4+ cells, as shown in Figs. 1 and 2.
igure 1 – Negative control. This ﬁgure shows the results of FCTA
lot lymphocytes and monocytes populations are identiﬁed by Fo
D4+ populations are viewed, with no cell labeled by HIV probe.5;1 9(2):163–169 165
Figs. 1 and 2 show the results of tropism determination for
two different patients: one with CCR5 tropism (A1–A6) and the
second with CXCR4 tropism (B1–B6). Initially, SSC versus CD4+
dot plot was used as gate strategies to monocytes and lympho-
cytes selection. In the ﬁrst sample (A1–A6) we  initially selected
the CD4+CXCR4+ cells population (A1). In the sequence, A2
determines the axis position to the positive CXCR4+ popula-
tion (ﬁrst quadrant), and A3 demonstrates that there are no
cells in the second quadrant (W1), which means a negative
result for X4 tropism. When we  look at the CCR5+ cells, A4
select the entire CD4+CCR5+ cell population (R2). In A5 we
have the deﬁnition of axis position to the CCR5+ population
(ﬁrst quadrant), and in A6 we  can detect HIV-infected cells in
the second quadrant (W2), which give us a deﬁnition of R5
tropism (Fig. 3).
To deﬁne CXCR4 tropism, in a second patient (B1–B6), the
analysis was performed in a similar way. The only difference
was that in B3 we found cells in w4 (second quadrant) which
indicates a positive result to CXCR4 HIV-1 tropism. No cells are
detected in the second quadrant (w5) in B6.
HIV-1 FCTA and geno2pheno tropism results were paired
and deﬁned 98% sensitivity, 96% speciﬁcity, and 98% posi-
tive 92% negative predictive values of FCTA, in comparison to
geno2pheno method. Sixty-ﬁve patients presented R5 tropism
according to both methods; only one patient had discordant
results. Three patients presents X4 tropism in both tests and
28 were dual tropic according to the two tests and in four sam-
ples the tests had discordant results. Table 1 shows the overall
performance of both tests.
The FCTA performance compared to geno2pheno was con-
sistent regardless of CD4+ cell count level. Table 2 displays the
test results of viral tropism for different CD4  strata.
DiscussionIn the present study, use of FCTA or geno2pheno algorithm
for determination of HIV-1 tropism in patients with different
strata of viral load and CD4 count provided practically iden-
tical results. The discovering of CCR5 antagonists and its use
 determination for seronegative individuals. In the ﬁrst
rward Scatter and CD4+ gate strategy. In second plot, only
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Figure 2 – CCR5 HIV tropism result model. To deﬁne CCR5 (A) and CXCR4 (B) tropism, we ﬁrst identiﬁed CD4+ cells,
HIV-infected cells (monocytes and lymphocytes) in R1, by using HIV Probe versus CD4 dot plot. The selected gate to infected
cells, was used to deﬁne HIV tropism, by using CD4+ versus CCR5 and CD4+ versus CXCR4 in dot plots for ﬁnal analysis.for the treatment of HIV-1 infection has led to development of
several HIV-1 tropism tests. A phenotypic test (Troﬁle) was the
ﬁrst assay created for that purpose. Since coreceptor tropism is
a requisite to the use of such drugs, the addition of these tests
to clinical practice has allowed health professionals to safely
select CCR5 antagonists as active drugs to compose antiretro-
viral regimens.24
Subsequently, other assays were developed: a Spanish
group created a different phenotypic assay (TROCAI), and
its results were compared with Troﬁle. TROCAI provided a
reportable result in all patients with viral load >500 HIV-1 RNA
copies/ml of plasma, and in 3/6 patients with <500 HIV RNA
copies/ml. Patients responding to maraviroc had a 0–0.41%
proportion of X4-using virus in supernatant of indicator cells.
Hence, it was used a threshold of 0.5% to categorize TROCAI
results as R5 (<0.5%) or dual/mixed (>0.5%). The concordancebetween TROCAI and Troﬁle (ES) was 22/24 (91.6%). In compar-
ison with the genotypic method it reached 22/26 (84.6%).23
Another test was developed to determine HIV-1 tropism
by genotyping, which used duplicate PCR ampliﬁcation of the
region encoding V3 loop. The evaluation of its performance
was attempted by comparing with results of the TROFILE
assay. The sensitivity of V3 genotyping in predicting CXCR4-
using viruses increased from 56.8% (with single PCR) to 68.2%,
with duplicate PCR (p = 0.13). The concordance between the
duplicate PCR approach and Troﬁle was of 76% for HIV-1 sub-
type B and 83% for non-B HIV-1 subtypes.25
Results genotypic assays are interpreted by using spe-
ciﬁc algorithms for deﬁnition of viral tropism of a speciﬁc
sample. In a study that evaluated the performance of
genotypic algorithms for predicting HIV tropism, PSSMX4X5
showed the best concordance with ES Troﬁle (82.6%; 95%
b r a z j i n f e c t d i s . 2 0 1 5;1 9(2):163–169 167
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I, 76.7–86.4%). Geno2pheno assay (false-positive rate, 20%)
howed the highest sensitivity to predict CXCR4 (76.7%;
5% CI, 61.8–87.5%), with a speciﬁcity of 73.6% (95% CI,
8.7–77.2%). Although no signiﬁcant difference in the accu-
acy of the bioinformatics tools was detected: 1% and 2.5%
ith Geno2pheno, respectively, when assessing HIV tropism
n samples from drug-naïve patients and in samples origi-
ated from treatment-experienced patients.21
In a study conducted by Vilchez et al.,16 a commercially
vailable FCTA kit (ViroTect Tropism Assay, Invirion, USA) was
ompared with TROFILE. In a total of 288 samples, FCTA pro-
ided less inconclusive results (6%) than TROFILE (13%). In
ddition, it was more  likely than standard TROFILE, to detect
XCR4 viruses in that population. Although a recent enhance-
ent of TROFILE increased the sensitivity of the test to detect
4 viruses, the study results indicate that FCTA may be a reli-
ble option for HIV-1 tropism determination.pism result model.
Geno2pheno methodology for HIV-1 tropism determina-
tion became a faster and cheaper alternative to phenotypic
tests. The available evidence indicate that geno2pheno pro-
vides an efﬁcient way to evaluate viral tropism, and it is
the test recommended by the European AIDS Clinical Society
(EACS) guidelines.25
According to some studies, CD4 count can be an impor-
tant predictive factor in determining viral tropism. Among
the algorithms, PSSMX4R5 showed the highest concordance
rate with ES TROFILE. The best correlation with TROFILE was
obtained in patients presenting with CD4+ cell count between
200 and 500 cells/mm3. In contrast, the weaker correlations
were found in patients with CD4+ cell count lower than
200 cells/mm3. In our work, there was no variation in test per-
formance across different strata CD4 cell counts. Of note, there
was a higher likelihood of identifying R5 viruses in patients
with CD4 cell count between 250 and 499 cells/mm3. It is well
168  b r a z j i n f e c t d i s . 2 0 1 5;1  9(2):163–169
Table 1 – HIV-1 tropism classiﬁcation according to the assay employed.
FCTAa classiﬁcation Geno2pheno classiﬁcation
CCR5b Dual infection CXCR4c Total
n (%) n (%) n (%)
CCR5 65 (100) 1 (3.4) 0 (0) 66
Dual Infection 0 (0) 28 (96.6) 4 (57.1) 32
CXCRd 0 (0) 0 (0) 3 (42.9) 3
Total 65 29 7
The overall concordance rate between both tests for identifying R5 virus was 100% (95% CI: 94.4–100%). Thirty-ﬁve patients were classiﬁed as
non-R5 (32 as duotropic/mixed viruses and three as X4) by geno2pheno. All but one sample were equally classiﬁed as non-R5 by FCTA: one
sample was classiﬁed as non-R5 by geno2pheno and as R5 by FCTA. These results correspond to 97.2% speciﬁcity (95% CI: 85.8–99.5%) of FCTA
using geno2pheno as gold standard. One additional sample could not be ampliﬁed in geno2pheno and was classiﬁed as duotropic by FCTA.
a FCTA, ﬂow cytometry tropism assay.
b Co-receptor C-C motif 5.
c Co-receptor C-X motif 4.
d Shade area is the speciﬁcity zone.
Sensitivity: 100%; speciﬁcity: 97.2%.
Table 2 – HIV-1 tropism according to CD4+ cell count
stratiﬁcation, and to the type of assay used.
Range CD4 counts Geno2pheno Total
CCR5 Non-CCR5 n (%)
n (%) n (%)
FCTA
(0–249) CCR5 9 (100) 0 (0) 9 (60)
Non-CCR5 0 (0) 8 (100) 8 (40)
(250–499) CCR5 23 (100) 1 (7.1) 24 (62.9)
Non-CCR5 0 (0) 11 (92.9) 11 (37.1)
(500–749) CCR5 18 (100) 0 (0) 18 (69.2)
Non-CCR5 0 (0) 8 (100) 8 (30.8)
r
6. Dragic T, Trkola A, Thompson DA, et al. A binding pocket for a
small molecule inhibitor of HIV-1 entry within the
transmembrane helices of CCR5. Proc Natl Acad Sci U S A.(>750) CCR5 15 (100) 0 (0) 15 (75)
Non-CCR5 0 (0) 7 (100) 7 (25)
known that X4 viruses emerge late in the course of HIV-1 infec-
tion, and our results are consistent with such contention.
In our study, FCTA presented a performance to deﬁne
viral tropism comparable to that found by using geno2pheno
methodology. FCTA has the advantage of being less time con-
suming, and has a lower cost than genotypic tests. It is also
technically simpler, and requires less sophisticated laborato-
ries than genotypic–based methods. Brazil has a large (over 90
sites), already in-place network of referral laboratories capa-
ble of performing ﬂow-cytometry assays for management of
HIV-infected patients in public health settings. On the other
hand, only of these laboratories are able to perform genotypic
tropism tests, and are responsible for receiving samples from
all Brazilian states.
Maraviroc, the only CCR5 antagonist approved to clinical
use, was recently made available for treating Brazilian HIV-
infected patients with previous failure to other drugs/classes.
It is expected a signiﬁcant increase in the number of tropism
tests referred to reference laboratories, and there is a concern
on their capability to timely respond to such an increasing
demand. A simpler, faster, tropism test would be of help
in such situation. It makes FCTA a potentially useful tool,
with signiﬁcantly lower costs, and shorter turnaround time.
It could be widely used, due to the already existing condi-
tions. Moreover, our results demonstrated that FCTA has ahigh concordance rate with geno2pheno algorithm in addi-
tion to not require nucleic acid ampliﬁcation. Other advantage
is its capacity to deﬁne viral tropism even in patients under
suppressive therapy, once it uses proviral DNA, and does not
depend on detectable HIV-1 RNA in plasma.
In conclusion, FCTA showed an excellent correlation with
genotypic assay and could represent a cheaper, faster and
easier tool. Its implementation could provide larger access of
Brazilian patients to treatment with CCR5 antagonists.
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